Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30677779 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL18669396 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL23647304 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL15754779 | 1.00 | ALDH1A1 (0.51) | ALDH1A1CNR1CNR2 | |
| SCHEMBL18669395 | 0.96 | ALDH1A1 (0.44) | ALDH1A1CNR1CNR2 | |
| SCHEMBL22638684 | 0.96 | ALDH1A1 (0.44) | ALDH1A1CNR1CNR2 | |
| SCHEMBL28605474 | 0.96 | ALDH1A1 (0.44) | ALDH1A1CNR1CNR2 | |
| SCHEMBL18669952 | 0.87 | CNR1 (0.40) | ALDH1A1CNR1CNR2 | |
| SCHEMBL31213151 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL18954218 | 0.85 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240175033-A1 | TMEM173 saRNA Compositions and Methods of Use | MINA THERAPEUTICS LIMITED (GB) | 2024-05-30 | — | — | US | disclosed |
| US-20240009291-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. | 2024-01-11 | — | — | US | disclosed |
| US-20210346381-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L.E.A.F. HOLDINGS GROUP LLC | 2021-11-11 | — | — | US | disclosed |
| US-20210128469-A1 | GAMMA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | L.E.A.F HOLDINGS GROUP LLC | 2021-05-06 | — | — | US | disclosed |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128469-A1 | GAMMA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | FPGS, DHFR, MTHFD1 | ALDH1A1 2731/4885CNR1 4076/4885CNR2 3833/4885 |
| US-20170368200-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | POLRMT, POLN, PHAX | ALDH1A1 4463/4885CNR1 4703/4885CNR2 4796/4885 |
| US-20240175033-A1 | TMEM173 saRNA Compositions and Methods of Use | SARNP, RBM17, CAPNS1 | ALDH1A1 3931/4885CNR1 4089/4885CNR2 4221/4885 |
| US-20240009291-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | MT-CO2, CYB5R3, COX5A | ALDH1A1 1529/4885CNR1 585/4885CNR2 284/4885 |
| US-20240216290-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | LIPA, NPC1L1, NPC1 | ALDH1A1 3082/4885CNR1 2897/4885CNR2 3697/4885 |
| US-20210346381-A1 | ALPHA POLYGLUTAMATED TETRAHYDROFOLATES AND USES THEREOF | DHFR, FPGS, MTHFD1 | ALDH1A1 2303/4885CNR1 4174/4885CNR2 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.